Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
- PMID: 15910483
- DOI: 10.1111/j.1478-3231.2005.01134.x
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
Abstract
Background/aims: A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update.
Methods: New data were presented, discussed and debated in an expert pre-meeting to draft a revision. The revised contents were finalized after discussion in a general meeting of APASL.
Results: Conceptual background, including the efficacy and safety profile of currently available and emerging drugs, was reviewed. Nineteen recommendations were formed and unresolved issues and areas for further study were suggested.
Conclusion: The current therapy of chronic hepatitis B is modestly effective but not satisfactory. The development of new drugs and new strategies is required to further improve the outcomes of treatment.
Similar articles
-
[New recommendations about treatment of chronic virus hepatitis of Asian-Pacific Association for Studying the Liver (APASL): what changed in 2008?].Eksp Klin Gastroenterol. 2008;(6):114-5. Eksp Klin Gastroenterol. 2008. PMID: 19334435 Russian. No abstract available.
-
Selecting appropriate management strategies for chronic hepatitis B: who to treat.Am J Gastroenterol. 2006;101 Suppl 1:S7-12. doi: 10.1111/j.1572-0241.2006.00446.x. Am J Gastroenterol. 2006. PMID: 16448451 Review.
-
New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.J Gastroenterol Hepatol. 2007 May;22(5):607-10. doi: 10.1111/j.1440-1746.2007.04969.x. J Gastroenterol Hepatol. 2007. PMID: 17444844 No abstract available.
-
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.HIV Med. 2008 Feb;9(2):82-8. doi: 10.1111/j.1468-1293.2007.00535.x. HIV Med. 2008. PMID: 18257771
-
Antiviral therapy for chronic hepatitis B: are we doing any good to patients?J Antimicrob Chemother. 2009 Aug;64(2):223-6. doi: 10.1093/jac/dkp189. Epub 2009 May 25. J Antimicrob Chemother. 2009. PMID: 19468026 Review.
Cited by
-
Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients.Hepatol Int. 2014 Jan;8(1):72-82. doi: 10.1007/s12072-013-9488-2. Epub 2013 Nov 28. Hepatol Int. 2014. PMID: 26202408
-
Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study.J Korean Med Sci. 2010 Jun;25(6):882-7. doi: 10.3346/jkms.2010.25.6.882. Epub 2010 May 24. J Korean Med Sci. 2010. PMID: 20514309 Free PMC article. Clinical Trial.
-
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.World J Gastroenterol. 2006 Nov 7;12(41):6715-21. doi: 10.3748/wjg.v12.i41.6715. World J Gastroenterol. 2006. PMID: 17075991 Free PMC article. Clinical Trial.
-
Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.Antimicrob Agents Chemother. 2009 Dec;53(12):5134-40. doi: 10.1128/AAC.00276-09. Epub 2009 Sep 21. Antimicrob Agents Chemother. 2009. PMID: 19770281 Free PMC article. Clinical Trial.
-
Evaluation and Determination of Quantitative Hepatitis B Surface Antigen Diagnostic Performance in Chronic Hepatitis B Virus-Infected Patients.Cureus. 2023 Jun 30;15(6):e41202. doi: 10.7759/cureus.41202. eCollection 2023 Jun. Cureus. 2023. PMID: 37525798 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
